MDT vs ABT
MDT and ABT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | MDTMedtronic plc | ABTABBOTT LABORATORIES |
|---|---|---|
| Market cap | $120.09B | $179.55B |
| P/E (TTM) | 23.1 | 28.9 |
| P/B | 2.39 | 3.45 |
| P/S | 3.3x | 4.1x |
| Dividend yield | 3.03% | 2.29% |
| Revenue | $37.54B(TTM) | $45.13B(TTM) |
| Revenue growth (YoY) | 8.4% | 5.7% |
| Net income | $430.00M(TTM) | $6.28B(TTM) |
| Earnings growth (YoY) | 3.0% | -51.3% |
| EPS, diluted | $4.06(TTM) | $3.57(TTM) |
| EBIT margin | 17.8% | 18.2% |
| ROE | 0.0% | 12.5% |
| ROIC | 7.0% | 8.3% |
| Piotroski F | 8/9 | — |
| 1y total return | +2.8% | -21.2% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: MDT vs ABT
| Metric | MDT | ABT |
|---|---|---|
| End value | $14.8K | $32.9K |
| Total return | +48.0% | +229.5% |
| CAGR | +3.9% | +12.2% |
| Volatility | 23.3% | 23.9% |
| Sharpe | 0.10 | 0.43 |
| Sortino | 0.14 | 0.62 |
| Max drawdown | -45.3% | -39.6% |
Based on 2600 common trading days, 2016-05-11 → 2026-09-14 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)